Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma

Evaluation of the Expression of the Human Epithelial Receptor 2 (HER2) in Gastric Carcinoma

Objective. To evaluate the HER2 expression on gastric adenocarcinoma from a Brazilian population and also to analyze the relations between the receptor and clinical characteristics, as well as the survival status. Materials and Methods. A retrospective analysis was conducted from January of 2008 to...

Full description

Saved in:

Bibliographic Details
Main Authors:	Roberto de Moraes Cordts Filho, Paulo Kassab, Laura Carolina Lopez Claro, Mabel Tatty de Medeiros Fracassi, Patrícia Colombo-Souza, Daniel Kenji Fukuhara, Fábio Rodrigues Thuler, Wilson Rodrigues de Freitas Junior, Elias Jirjoss Ilias, Carlos Alberto Malheiros
Format:	Article
Language:	English
Published:	Wiley 2016-01-01
Series:	The Scientific World Journal
Online Access:	http://dx.doi.org/10.1155/2016/7951365
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Assessment of the Body Composition and the Loss of Fat-Free Mass through Bioelectric Impedance Analysis in Patients Who Underwent Open Gastric Bypass
by: Wilson Rodrigues de Freitas Junior, et al.
Published: (2014-01-01)

Targeting of the HER2/HER3 signaling axis overcomes ligand‐mediated resistance to trastuzumab in HER2‐positive breast cancer
by: Satomi Watanabe, et al.
Published: (2019-03-01)

The EGF Receptor and HER2 Participate in TNF-α-Dependent MAPK Activation and IL-8 Secretion in Intestinal Epithelial Cells
by: Humberto B. Jijon, et al.
Published: (2012-01-01)

The Utility of Endoscopic Ultrasound Guided Fine Needle Aspiration in the Diagnosis of Infectious Diseases—Report of Three Cases
by: Mauro Ajaj Saieg, et al.
Published: (2013-01-01)

Natural killer cells occupy unique spatial neighborhoods in HER2- and HER2+ human breast cancers
by: Femke A. I. Ehlers, et al.
Published: (2025-01-01)

Comparison between Real-Time Quantitative PCR Detection of HER2 mRNA Copy Number in Peripheral Blood and ELISA of Serum HER2 Protein for Determining HER2 Status in Breast Cancer Patients
by: Maria Savino, et al.
Published: (2009-01-01)

The Clinicopathological Features and Prognostic Significance of HER2-Low in Early Breast Tumors Patients Prognostic Comparison of HER-Low and HER2-Negative Breast Cancer Stratified by Hormone Receptor Status
by: Sanaa Gamrani, et al.
Published: (2023-01-01)

Effect of Estrogen Receptor on the Relationship Between HER2 Immunohistochemistry Score and Pathological Complete Response to Neoadjuvant Treatment in HER2-Positive Breast Cancer
by: Miaomiao Jia, et al.
Published: (2024-01-01)

The Real-World Clinical Outcomes of Heavily Pretreated HER2+ and HER2-Low Metastatic Breast Cancer Patients Treated with Trastuzumab Deruxtecan at a Single Centre
by: Anna-Maria Lazaratos, et al.
Published: (2024-12-01)

Neratinib and the Role of Anti‐HER2 Therapy in Salivary Duct Carcinoma
by: Martina Napolitano, et al.
Published: (2025-01-01)

HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2024-11-01)

Role of Fcγ receptors in HER2-targeted breast cancer therapy
by: Hope S Rugo, et al.
Published: (2022-01-01)

Comparison of HER2-Targeted Antibodies for Fluorescence-Guided Surgery in Breast Cancer
by: Solmaz AghaAmiri, et al.
Published: (2021-01-01)

HER-2 Expression in Immunohistochemistry Has No Prognostic Significance in Gastric Cancer Patients
by: Agnieszka Halon, et al.
Published: (2012-01-01)

Maintenance Therapy with Trastuzumab in Her2 Positive Metastatic Parotid Ductal Adenocarcinoma
by: Muhammad Shahid Iqbal, et al.
Published: (2014-01-01)

Expression Profile of Tyrosine Phosphatases in HER2 Breast Cancer Cells and Tumors
by: Maria Antonietta Lucci, et al.
Published: (2010-01-01)

PIK3CA mutational status in tissue and plasma as a prognostic biomarker in HR+/HER2− breast cancer
by: Eduardo Terán, et al.
Published: (2024-09-01)

CD36 enrichment in HER2-positive mesenchymal stem cells drives therapy refractoriness in breast cancer
by: Lorenzo Castagnoli, et al.
Published: (2025-01-01)

Publisher Correction: HER2-related biomarkers predict clinical outcomes with trastuzumab deruxtecan treatment in patients with HER2-expressing metastatic colorectal cancer: biomarker analyses of DESTINY-CRC01
by: Salvatore Siena, et al.
Published: (2025-01-01)

Clinical characteristics, metastasis patterns, and treatment outcomes of HER2-low breast cancer
by: Maria Elena Lacruz, et al.
Published: (2025-02-01)

Mechanisms of Resistance to Trastuzumab and Novel Therapeutic Strategies in HER2-Positive Breast Cancer
by: Andrea L. A. Wong, et al.
Published: (2012-01-01)

A Novel Bimodal Imaging Agent Targeting HER2 Molecule of Breast Cancer
by: Wei Lv, et al.
Published: (2018-01-01)

Blood Genome-Wide Transcriptional Profiles of HER2 Negative Breast Cancers Patients
by: Ovidiu Balacescu, et al.
Published: (2016-01-01)

Recognition of HER2 expression in hepatocellular carcinoma and its significance in postoperative tumor recurrence
by: Ji‐Hua Shi, et al.
Published: (2019-03-01)

Discussion on the mechanism of HER2 resistance in esophagogastric junction and gastric cancer in the era of immunotherapy
by: Yan Zhang, et al.
Published: (2025-12-01)

Targeting PCSK9, through an innovative cVLP-based vaccine, enhanced the therapeutic activity of a cVLP-HER2 vaccine in a preclinical model of HER2-positive mammary carcinoma
by: Laura Scalambra, et al.
Published: (2025-01-01)

‘Her Room Was Her World’: Nellie Sloggett and North Cornish Folklore
by: Simon Young
Published: (2017-12-01)

HER-2/neu Amplification Testing in Breast Cancer by Multiplex Ligation-Dependent Probe Amplification in Comparison with Immunohistochemistry and In Situ Hybridization
by: Cathy B. Moelans, et al.
Published: (2009-01-01)

Her mistletoe miracle
by: FOx Roz Denny
Published: (2008)

Review of the clinical status of cardiotoxicity of HER-2 positive breast cancer targeted therapeutic drugs
by: Xiang Zhang, et al.
Published: (2025-02-01)

Intrathecal trastuzumab: immunotherapy improves the prognosis of leptomeningeal metastases in HER-2+ breast cancer patient
by: Nu T. Lu, et al.
Published: (2015-09-01)

CARDIAC-STAR: prevalence of cardiovascular comorbidities in patients with HR + /HER2 − metastatic breast cancer
by: Susan Dent, et al.
Published: (2025-01-01)

Trastuzumab in Esophagogastric Cancer: HER2-Testing and Treatment Reality outside Clinical Studies in Germany
by: Kirsten Merx, et al.
Published: (2016-01-01)

Impact of HER2-targeting antibody drug conjugates in treatment strategies for patients with breast cancer
by: Hanghang Ma, et al.
Published: (2025-02-01)

Looking beyond the ER, PR, and HER2: what’s new in the ARsenal for combating breast cancer?
by: Tryambak Pratap Srivastava, et al.
Published: (2025-01-01)

HER-SAFE study design: an open-label, randomised controlled trial to investigate the safety of withdrawal of pharmacological treatment for recovered HER2-targeted therapy-related cardiac dysfunction
by: Robin Chung, et al.
Published: (2025-02-01)

PTPN9 regulates HER3 phosphorylation during trastuzumab treatment and loss of PTPN9 is a potential biomarker for trastuzumab resistance in HER2 positive breast cancer
by: Abul Azad, et al.
Published: (2025-01-01)

Release of Type 2 Cytokines by Epithelial Cells of Nasal Polyps
by: Monica Boita, et al.
Published: (2016-01-01)

A New Monoclonal Antibody Demonstrates That Muc4, the Intramembrane Ligand for Erbb2/Her2/Neu, Is Overexpressed in Multiple Carcinomas
by: Jin Zhang, et al.
Published: (2002-01-01)

Comparative Study between Quantitative Digital Image Analysis and Fluorescence In Situ Hybridization of Breast Cancer Equivocal HER2 2+ Cases
by: E. Ayad, et al.
Published: (2014-01-01)